Background: We previously demonstrated that combination bone marrow derived cultured mesenchymal
stromal cell (BM-MSC) with bone marrow derived unselected mononuclear cell (BM-MNC)
may help induce angiogenesis in diabetic patients with critical limb ischemia. In
this new randomized Phase II/III clinical trial, we compared autologous BM-MSC with
BM-MNC (Group A) versus BM-MNC alone (Group B) in severe lower limb ulcers secondary
to critical limb ischemia with the aim of avoiding amputations.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
